• Fresenius Q3/26 adjusted core EPS rose 15% year over year to EUR 0.72.
• Revenue before special items climbed 6% to EUR 5.8 billion; EBIT margin before special items widened to 11%.
• An exclusive development agreement with WuXi Biologics provides access to up to 37 potential first-to-market biosimilar candidates.
• The group raised its FY26 EBIT margin indication before special items to above 11.5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2427898_en) on November 04, 2026, and is solely responsible for the information contained therein.